Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

CASSAVA SCIENCES, INC.

(SAVA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Sector Update: Health Care Stocks Lacking Much Traction

07/15/2021 | 01:38pm EDT


ę MT Newswires 2021
All news about CASSAVA SCIENCES, INC.
09/25(SAVA) DEADLINE : Did You Suffer a Substantial Loss? Contact Johnson Fistel Regarding Lead..
PR
09/23CASSAVA SCIENCES : ROSEN, A TOP RANKED LAW FIRM, Encourages Cassava Sciences, Inc. Investo..
PR
09/23CASSAVA SCIENCES : Shares Extend Gains in Heavy Trading
MT
09/23SAVA INVESTOR LAWSUIT DEADLINE REMIN : Bernstein Liebhard LLP Reminds Investors of the Dea..
PR
09/23CASSAVA SCIENCES : Announces Top-line Results of 12-month Interim Analysis from Open-label..
AQ
09/22CASSAVA SCIENCES : Says Open-Label Trial of Simufilam Shows Improved Cognition Scores in A..
MT
09/22Cassava Sciences Announces Top-line Results of 12-month Interim Analysis from Open-labe..
GL
09/22Cassava Sciences Announces Top-Line Results of 12-Month Interim Analysis from Open-Labe..
CI
09/21INVESTOR ALERT : Kirby McInerney LLP Reminds Investors That a Securities Class Action Laws..
BU
09/20CASSAVA SCIENCES, INC.(NASDAQCM : SAVA) added to S&P Global BMI Index
CI
More news
Analyst Recommendations on CASSAVA SCIENCES, INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -21,7 M - -
Net Debt 2021 - - -
P/E ratio 2021 -103x
Yield 2021 -
Capitalization 2 479 M 2 479 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 37,2x
Nbr of Employees 11
Free-Float 93,5%
Chart CASSAVA SCIENCES, INC.
Duration : Period :
Cassava Sciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CASSAVA SCIENCES, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 61,94 $
Average target price 140,67 $
Spread / Average Target 127%
EPS Revisions
Managers and Directors
Remi Barbier Chairman, President & Chief Executive Officer
Eric J. Schoen Chief Financial Officer
Nadav Friedmann Director, Chief Operating & Medical Officer
James W. Kupiec Chief Clinical Development Officer
Michael Zamloot Senior Vice President-Technical Operations
Sector and Competitors
1st jan.Capi. (M$)
CASSAVA SCIENCES, INC.808.21%2 479
GILEAD SCIENCES, INC.22.19%89 259
BIONTECH SE309.08%80 542
WUXI APPTEC CO., LTD.34.39%68 685
REGENERON PHARMACEUTICALS32.25%66 425
VERTEX PHARMACEUTICALS-22.31%47 634